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Aims: Riata® implantable cardioverter-defibrillator (ICD) leads from St. Jude Medical are prone to mal-
function. This study aimed to describe the rate of this lead's malfunction in a very long-term follow-up.
Methods: This single-centre observational study included 50 patients who received a Riata 7Fr dual-coil
lead between 2003 and 2008. Follow-up was conducted both in person and remotely, and analysed at 8-
month intervals. We evaluated the rates of cable externalization (CE), electrical failure (EF), and the
interaction of these two complications. Structural lead failure was defined as radiographic CE. Over-
sensing of non-cardiac signal or sudden changes in impedance, sensing, or pacing thresholds constituted
EF.
Results: During a mean follow-up of 10.2 ± 2.9 years, 16 patients (32%) died. We observed lead mal-
function in 13 patients (26%): three (23%) due to CE, six (46%) to EF and four (31%) to both complications.
Of the malfunctioning leads, 77% failed after seven years of follow-up. The incidence rate (IR) of overall
malfunction per 100 patients per year was 0.9 during the first seven years post-implantation, increased
to 7.0 after the 7th year and more than doubled (to 16.7) after 10 years. Beyond seven years post-
implantation, IR per 100 patient-years increased in both EF and CE (from 0.6 to 5.6 vs. 0.3 to 4.2,
respectively). Presence of CE was associated with a 4-fold increase in the proportion of EF.
Conclusion: The incidence of Riata ICD lead malfunction, both for EF and CE, increased dramatically after
seven years and then more than doubled after 10 years post-implantation.
Copyright © 2019, Indian Heart Rhythm Society. Production and hosting by Elsevier B.V. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction cable externalization (CE) [4,5]. An increased rate of electricalSince 2007, when the Riata® implantable cardioverter-
defibrillator (ICD) leads were first associated with significantly
more cardiac perforations [1,2], many cases related to Riata lead
malfunction have been reported. In 2011, the United States Food
and Drug Administration (FDA) issued a class I advisory for the
Riata and Riata ST ICD leads [3]. This advisory described design
problems in silicone-coated Riata leads, resulting in conductorrdiovascular Clinic Institute,
, 08036, Barcelona, Catalonia,
.
Rhythm Society.
ociety. Production and hosting byfailure (EF) also has been observed [4]. Although most observa-
tional studies have demonstrated a significantly increased rate of EF
in the setting of CE (between 3 and 6 times higher when CE was
present, compared to leads without externalization), this specific
association remains unclear [4,6,7]. The use of routine radiographic
screening for CE has accordingly been questioned, in particular
because the incidence of EF without externalization is not trivial
and lead revision (and especially lead extraction) has been associ-
ated with a higher rate of major complications [4,5].
Cable externalization is the primary cause of malfunction, with a
prevalence ranging from 11 to 43% [6,8e10]. The overall estimated
proportion of EF is 6.3%, but the rate is 17.3% in the presence of CE
and just 2.7% without externalization [6]. It is important to
emphasize that EF rates do not appear to differ between lead
subtypes. Despite the reported association between CE and EF and aElsevier B.V. This is an open access article under the CC BY-NC-ND license (http://
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compared with 7Fr leads, similar proportions of EF have been noted
for both 7Fr and 8Fr leads [4,6]; this suggests that the smaller
calibre 7Fr lead might be more susceptible to outside-in abrasion,
rather than inside-out abrasion [11].
Several studies have focused on the short-term performance of
the Riata ICD lead; however, only two studies [5,12] have investi-
gated the associated long-term complications, with a mean follow-
up duration of 8.9 and 7 years, respectively.
The aim of this study was to describe, over the very long term
(>10 years), the malfunction rate and reliability of the Riata 7Fr
dual-coil lead by examining the rates of EF, CE, and the interaction
of these two complications.
2. Methods
This single-centre observational study included all patients who
underwent Riata ICD lead implantation between 2003 and 2008
using a 7Fr model with a dual-coil design.
The primary outcome measures included rates of lead failure
(structural lead failure and/or EF) and time to any malfunction.
Follow-up included routine clinical visits for device interrogation
(45 days post-implantation and at 8-month intervals) and remote
monitoring (Merlin.net™) when available. All death events were
strictly verified for precise measurement of survival from the date
of implantation.
Structural lead failure was defined as a lead presenting an
externalization of conductors, insulation defect, or fracture [13].
Externalizationwas defined as conductor(s) visible outside the lead
body on chest X-ray or cinefluoroscopy, as reviewed by radiologists
and/or electrophysiologists (Fig. 1A). We sub-classified CE into four
groups according to the topography of the mechanical malfunction:
A, distal to superior vena cava (SVC)-coil; B, distal to clavicle
including SVC-coil; C, near clavicle; and D, clavicle to pulse gener-
ator (Fig. 1B) [14].
Electrical failure was defined as one or more of the following
lead malfunctions: 1) Oversensing of non-physiological electrical
noise artefacts; 2) conductor impedance out of range (<200U or
>2000U) or a sudden change (>100% increase or> 50% decrease) in
the stable baseline; 3) a change in the high-voltage impedance
(>200U or< 50U); 4) an abrupt increase in capture threshold
(>100% increase over baseline); and 5) an unexpected decrease in
R-wave sensing (>50% decrease from baseline) [14]. Lead dislodg-
ments and physiological oversensing were not considered EF.
A proactive lead strategy was implemented that consisted of
systematic lead extraction or lead abandonment (especially in pa-
tients with multiple comorbidities) in the case of battery replace-
ment and radiographic detection of CE, regardless of electrical leadintegrity. Subsequently, a new electrode was implanted during the
replacement of the generator.
2.1. Statistical analysis
Categorical variables, represented as proportions, were
compared using the chi-square test. Continuous variables were
expressed as means, and their standard deviation (SD) and com-
parisons between groups were made using the Student t-test.
The incidence rate (IR) per 100 patients per year (PY) for lead
malfunctionwas calculated considering the follow-up duration and
then specifically for follow-up after the 7th and the 10th year post-
implantation. Failure-free survival in the long term was calculated
using the Kaplan-Meier method. For each time interval, the prob-
ability of failure-free survival was calculated as the number of Riata
malfunction-free surviving patients divided by the number of pa-
tients at risk. Patients who had died and those with a new lead
implanted for causes other than lead failure were considered
“censored” and were not counted in the denominator.
All of the tests were two-sided. A p-value <0.05 was considered
to be statistically significant. Statistical analysis was conducted
using IBM SPSS Statistics v19.0 (Chicago, Illinois, USA).
3. Results
From 2003 through 2008, 50 patients underwent Riata ICD lead
implantation in our unit (Fig. 2). The mean follow-up duration was
10.2± 2.9 years. No patients were lost to follow-up. All the leads
were Riata 7Fr, dual-coil, passive-fixation. The primary patient
characteristics of the study population are listed in Table 1. During
follow-up, all living patients who still had the Riata lead underwent
battery replacement. Moreover, remote monitoring was initiated at
the time of replacement (n¼ 29, 58%).
Overall, we detected lead malfunction in 13 patients: three due
to CE, six to EF and four to both complications. The IR, considering
an absolutemalfunction rate of 26% involving 13 leads and 469.8 PY
of post-implantation follow-up, was 2.7 per 100 PY. Of the 13
malfunctioning leads, 10 (77%) failed after 7 years of follow-up.
Thus, during the first 7 years, the malfunction rate was 0.9 per
100 PY. However, this rate drastically increased to 7.0 after the
seventh year and to 16.7 per 100 PY after 10 years post-
implantation. The overall Kaplan-Meier survival curve for the
Riata leads declined sharply after seven years, from 93% to just 34%
after 14 years (Fig. 3).
All-cause mortality was 16/50 (32%), with no deaths attributed
to lead failure (Table 2). In addition to the patients with lead mal-
function, four patients required implantation of new non-Riata
leads: two due to infective endocarditis (IE), one because of an
upgrade to biventricular ICD in a patient with left subclavian
venous thrombosis, and one due to physiological oversensing. In
total, we removed the lead in six patients (35%): two with IE and
four with lead failure. In the other 11 patients (65%) who received a
new implant (nine due to lead malfunction, one to physiological
oversensing, and one to a need for biventricular ICD), the cable was
abandoned without detecting any associated complications.
3.1. Electrical failure
During complete follow-up, 10 patients (20%) presented with
EF: four cases were associated with CE. The mean time to appear-
ance was 10.0± 2.9 years. Eight leads (80%) failed after seven years
of follow-up, increasing the IR in patients with EF from 0.6 to 5.6
per 100 PY after seven years post-implantation. Univariate analysis
showed that none of the baseline characteristics was a predictor of
EF.
Fig. 1. A. Cable externalization between both coils (zones A1-A2). Yellow arrow indicates the affected area. Fig. 1B. Cable externalization sub-classified according to the topography
of the mechanical dysfunction: D, clavicle to pulse generator; C, near clavicle; B, distal to clavicle including SVC-coil; A, distal to SVC-coil. In turn, that area between both coils is
divided into: SVC-coil to the tricuspid valve annulus (A3); just in the tricuspid valve annulus level (A2); tricuspid valve annulus to the right ventricle-coil (A1) [14]. SVC, superior vena
cava.
Fig. 2. This flow diagram illustrates the number of patients included in this study. ICD, implantable cardioverter-defibrillator; CE, cable externalization; EF, electrical failure; IE, infective
endocarditis; PO, physiological oversensing; LSVO, left subclavian vein occluded.
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physiological noise on the ventricular sensing channel (8 patients,
80%). In two of the 10 patients, EF was detected by remote moni-
toring and in five patients it was diagnosed at the on-site hospital
visit. In one case, EF occurred after the application of a programmed
10 J shock in a patient with known CE (previously revealed by X-
ray). The two remaining patients with EF were treated at the
emergency department due to inappropriate ICD shocks. In one of
these patients, several inappropriate ICD shocks were due to non-
physiological noise following an appropriate shock because of
ventricular tachycardia.3.2. Cable externalization
Radiographic data were available on 45 (90%) patients. We
found CE in seven (14%) patients; mean time to appearance was11± 2.5 years. The IR of CE increased from 0.3 to 4.2 per 100 PYafter
seven years post-implantation. The most common location of
externalizationwas zone A (n¼ 7,100%), described by Demirel et al.
[14] as that area between both coils: 1 (14%) was between the SVC-
coil and the tricuspid valve annulus (A3), 4 (57%) were just at the
tricuspid valve annulus level (A2) and 2 (29%) were between the
tricuspid valve annulus and the right-ventricle coil (A1) (Fig. 1B).3.3. Interaction between electrical failure and cable externalization
No differences were found between EF and CE rates: 10 cases vs.
7 cases, respectively, during the whole follow-up period (p¼ 0.42);
6 vs. 5 after the 10th year (p¼ 0.73). The presence of CE was
associated with a 4-fold increase in the proportion of EF (4/7 (57%)
vs. 6/43 (14%) with no CE, p¼ 0.008).
Table 1
Baseline characteristics. SD, standard deviation; CAD, coronary artery disease; HCM,
hypertrophic cardiomyopathy; BrS, Brugada syndrome; LQTS, long QT syndrome;
ARVD, arrhythmogenic right ventricular dysplasia; LVEF, left ventricular ejection
fraction; ICD, implantable cardioverter-defibrillator.
Variables at baseline All (n¼ 50)
Sex, male, n (%) 43 (86)
Age at implantation, years, mean ± SD 59± 14
Underlying cardiac disease
CAD, n (%) 27 (54)
Non-ischemic cardiomyopathy, n (%) 10 (20)
HCM, n (%) 6 (12)
BrS, n (%) 4 (8)
LQTS, n (%) 2 (4)
ARVD, n (%) 1 (2)
LVEF, mean± SD 41± 16
Atrial fibrillation, n (%) 4 (8)





Pacemaker dependency, n (%) 2 (4)
Left-sided implant, n (%) 49 (98)
Follow-up time, years, mean± SD 10.2± 2.9
Fig. 3. Kaplan-Meier survival curve. The incidence of lead malfunctions dramatically
increased after the 7th year post-implantation (blue line) and was especially evident
after 10 years (red line).
Table 2
Causes of death in our cohort.
Cause of death n¼ 16
Cardiovascular diseases, n (%) 6 (37,5)
Cardiogenic shock, n (%) 3 (19)
Heart failure, n (%) 3 (19)
Septic shock, n (%) 2 (12,5)
Cerebrovascular disease, n (%) 3 (19)
Ischemic stroke, n (%) 1 (6)
Intracerebral haemorrhage 1 (6)
Glioblastoma, n (%) 1 (6)
Respiratory diseases 3 (19)
Pneumonia, n (%) 2 (12,5)
Lung cancer, n (%) 1 (6)
Digestive diseases 2 (12,5)
Intestinal ischemia, n (%) 1 (6)
Peritonitis, n (%) 1 (6)
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The main finding of this study was that the malfunction rate of
7Fr dual-coil Riata ICD leads increased for both EF and CE over verylong-term follow-up, especially after 10 years post-implantation.
The 14-year lead survival rate was just 34%, compared to 93% at
seven-year follow-up. The presence of CE was associated with a
four-fold increase in the proportion of EF, compared to no CE. Lead
abandonment rather than extraction was not associated with a
higher rate of adverse consequences.
Several studies [5,12] have found an exponential increase in the
malfunction rate, especially in leads surviving more than five years.
Our study, with a mean follow-up longer than 10 years, confirmed
that exponential increase and showed an even sharper curve after
10 years. Thus, while the IR increased to 7.0 per 100 PY after the
seventh year, it more than doubled (16.7 per 100 PY) after 10 years
post-implantation. During the entire follow-up period, 13 lead
failures were observed, accounting for an IR of 2.7 per 100 PY. The
difference between this finding and the IR of 1.17 per 100 PY re-
ported in themeta-analysis by Providencia et al. [13] is likely due to
our longer follow-up: if only the first 10 years of follow-up were
considered, both IRs would be quite similar (1.4 per 100 PY). Indeed,
10 of the 13 leads (77%) failed after seven years of follow-up. On the
other hand, we analysed a 7Fr Riata model. Some studies have
suggested that thinner leads may be associated with an increased
likelihood of malfunction [13,15], while other researchers report no
differences based on lead caliber [12].
No differences were found between EF and CE rates during the
whole follow-up period nor after the 10th year. We observed an
exponential increase over time in both EF and CE (0.6e5.6 per 100
PY vs. 0.3 to 4.2 PY, respectively). Although the cumulative inci-
dence of EF was similar to previous studies at 8 years (4% in our
cohort vs. 5.2% in the registry of Parkash et al. [5]), during the
complete follow-up it rose to 20%. On the other hand, over the
whole follow-up period the 14% CE rate was within the lower range
of previous studies (11%e43%) [6] but was only 2% at eight years.
This low percentage could be related to the 7Fr lead calibre, which
has been associated with a lower proportion of CE [6,16]. We found
a significantly increased incidence of EF in the setting of CE (57% vs
14%, respectively, p¼ 0.008). Our data are consistent with those of
Steinberg et al. [17] (25% vs. 4.7%), Zeitler E [6] et al. (17.3% vs. 2.7%)
and Larsen et al. [7] (19.2% vs. 4.9%). It should bementioned that we
implanted a new lead in patients with structural lead failure, which
could have increased the difference observed between the two
types of malfunction. Similar to previous reports [12], oversensing
of non-physiological noise was the main mode of presentation of
EF.
Regarding the decision to extract or abandon a malfunctioning
lead, Maytin M and colleagues [17] point out that extraction of the
Riata leads could be performed safely by experienced operators.
However, in other series lead extraction has been related to a high
risk of complications (18.6% vs. 5.2% for abandonment, p< 0.0001)
[5]. In our study, the most common strategy was abandonment of
the lead (65% vs. 35%), which did not lead to any complications.
Given the high failure rate of Riata ICD leads more than 10 years
post-implantation, remote monitoring could be recommended to
improve early detection of EF. In addition, it could be useful to
perform serial radiographic exams, especially after 10 years post-
implantation, given the likely association between EF and CE.
5. Limitations
The present study has several limitations that must be
acknowledged. Results were obtained in a single centre, therefore,
the generalizability of our results should be viewed with caution.
The length of time to CE could not be determined with precision
because radiographic exams were performed according to physi-
cian discretion rather than annually. As a consequence, the EF rate
might have been overestimated compared to that of CE.
R. San Antonio et al. / Indian Pacing and Electrophysiology Journal 19 (2019) 140e144144Nevertheless, since all living patients underwent battery replace-
ment, results of one or more radiographic exams were available for
each patient over a long follow-up period.6. Conclusion
The incidence of 7Fr dual-coil Riata ICD lead malfunctions
dramatically increased following the seventh year post-
implantation and more than doubled after 10 years post-
implantation in both EF and CE cases. A combination of remote
monitoring and regular radiographic follow-up, particularly after
10 years, could help with appropriate decision making.Conflict of interest statement
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